Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumours

Next Previous
X
Search
Trial Profile

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumours

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Liver cancer; Male breast cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer; Uveal melanoma
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Sponsors AstraZeneca; MedImmune

    • Most Recent Events

    • 19 Apr 2023 Results assessing the functional impact of myeloid cells on the immuno-oncology response and in particular, suppressive (M2) tumor associated macrophages (TAMs) of durvalumab in patients with advanced non-small cell lung cancer, presented at the 114th Annual Meeting of the American Association for Cancer Research.
    • 13 Apr 2022 Results of an analysis to identify single and combined biomarkers of the tumor immune contexture in association with long-term OS in advanced NSCLC patients treated with Durvalumabpresented at the 113th Annual Meeting of the American Association for Cancer Research
    • 01 Jul 2021 Results( n=74)evaluating peripheral blood TCR-beta chain repertoires in advanced NSCLC before and after treatment with durvalumab published in the Cancer Immunology Immunotherapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top